Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function
Journal of Clinical Lipidology · 2026-04 · 20 (4) · 770-777
DOI: 10.1016/j.jacl.2026.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026-04. Verfasst von Maximilian Seidel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Germany (Seidel, Seibert, Doevelaar, Rohn, Bertram, Kolodzie…. Hauptthemen laut MEDLINE: Inflammation, PCSK9 Inhibitors, Lipoproteins, HDL. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, Novartis Germany.
Abstract (Originalsprache)
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition effectively lowers low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk, but its pleiotropic effects remain insufficiently defined. This study examined whether PCSK9 inhibition influences vascular and systemic inflammation and high-density lipoprotein (HDL) antioxidant function. OBJECTIVE: To investigate the effects of PCSK9 inhibition on vascular inflammation, systemic inflammatory markers, and HDL antioxidant function in a real-world patient cohort. MATERIAL AND METHODS: ). Systemic inflammation was evaluated via high-sensitivity C-reactive protein (hsCRP) and a predefined cytokine panel. RESULTS: did not change (1.190-1.210, P = .3438). Interferon gamma-induced protein (IP) 10 (P = .0141) and interleukin (IL)-2 (P = .0371) decreased, whereas hsCRP and other cytokines-including IL-1β, IL-4, IL-6, IL-8, IL-10, IL-17A, tumor necrosis factor-α, monocyte chemotactic protein-1, interferon-γ, and free radicals-remained unchanged (all P > .05). CONCLUSION: and IP-10 without changing global inflammatory response or antioxidant function of HDL, which might indicate a decrease in chronic vascular inflammation without an undesired broad systemic immune alteration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Germany (Seidel, Seibert, Doevelaar, Rohn, Bertram, Kolodziej, Babel, and Westhoff). Electronic address: maximilian.seidel@elisabe…
- Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Germany (Seidel, Seibert, Doevelaar, Rohn, Bertram, Kolodziej, Babel, and Westhoff).
- Department of Cardiology, University Hospital Ruppin-Brandenburg, Medical School Theodor Fontane, Neuruppin, Germany (Pagonas).
- Practice for Kidney Diseases, Dialysis and Apheresis, 44789 Bochum, Germany (Korth).
Förderung
- Novartis
- Novartis Germany
Zitieren
APA
Seidel, M., Seibert, F. S., Doevelaar, A., Rohn, B., Bertram, S., Kolodziej, J. F., Pagonas, N., Korth, J., Babel, N., & Westhoff, T. H. (2026). Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function. Journal of Clinical Lipidology, 20(4), 770-777. https://doi.org/10.1016/j.jacl.2026.02.003
Vancouver
Seidel M, Seibert FS, Doevelaar A, Rohn B, Bertram S, Kolodziej JF, et al. Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function. Journal of Clinical Lipidology. 2026;20(4):770-777. doi:10.1016/j.jacl.2026.02.003
BibTeX
@article{Seidel2026,
author = {Seidel, Maximilian and Seibert, Felix S and Doevelaar, Adrian and Rohn, Benjamin and Bertram, Sebastian and Kolodziej, Jonas F and Pagonas, Nikolaos and Korth, Johannes and Babel, Nina and Westhoff, Timm H},
title = {Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {4},
pages = {770--777},
doi = {10.1016/j.jacl.2026.02.003}
}
EUVIMED